검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vincristine Sulfate (Vincristine Sulfate) AIDS Malignancy Consortium·Lugano Classification Limited Stag… ORR 95% | ||||
|---|---|---|---|---|---|
Overview Program | Zanubrutinib | Etoposide Phosphate | SGN-30 (monoclonal antibody) | Vincristine Sulfate | Aldesleukin |
Overview Company | Juan P. Alderuccio, MD | Celgene | Seagen Inc. | AIDS Malignancy Consortium | Genzyme, a Sanofi Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CNS Lymphoma | B-cell Non Hodgkin Lymphoma | Hodgkin Disease | Lugano Classification Limited Stage Hodg | Gastric Cancer |
Overview Indication | CNS Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Hodgkin Disease; Lymphoma, Large-Cell | Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | ACTIVE | RECRUITING | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling | Etoposide phosphate is a prodrug that is converted to its active moiety, etoposide, by dephosphorylation | — | targeting, as many cancer cells overexpress folate receptor | checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity |
MoA Biomarker | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | — | — | biomarkers were assessed | biomarkers |
PK/PD Half-life | — | 119 days | — | — | 2 h |
PK/PD Species | Rat | Rabbit | — | Mouse | Mouse |
PK/PD Animal (cat.) | Rat | In vitro | — | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | PK | pharmacokinetic | — | PD | biodistribution |
Toxicology Species | Rat | Rat, Rabbit | — | Mouse, Hamster | Mouse |
Toxicology Animal (cat.) | Rat | Rat | — | Mouse | Mouse, In vitro |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | hepatotoxicity 6 | thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literatur | thrombocytopenia have been reported | hepatotoxicity: knowledge gap identification based on the irAOP concept |
Clinical Primary efficacy | ORR 95.2% | ORR 77.3% | ORR 64% | ORR 95% | ORR 33.3% |
Clinical ORR | 95.2% | 77.3% | 64% | 95.0% | 33.30% |
Clinical PFS | 61.4 | 38 | — | — | — |
Clinical OS | NA | — | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT00732498 | ClinicalTrials.gov NCT01909934 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT01993719 |
Clinical Data Tier / Score | S · 78 | A · 73 | C · 53 | B · 70 | C · 46 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vincristine Sulfate (Vincristine Sulfate) AIDS Malignancy Consortium·Lugano Classification Limited Stag… ORR 95% | ||||
|---|---|---|---|---|---|
Overview Program | Zanubrutinib | Etoposide Phosphate | SGN-30 (monoclonal antibody) | Vincristine Sulfate | Aldesleukin |
Overview Company | Juan P. Alderuccio, MD | Celgene | Seagen Inc. | AIDS Malignancy Consortium | Genzyme, a Sanofi Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CNS Lymphoma | B-cell Non Hodgkin Lymphoma | Hodgkin Disease | Lugano Classification Limited Stage Hodg | Gastric Cancer |
Overview Indication | CNS Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Hodgkin Disease; Lymphoma, Large-Cell | Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | ACTIVE | RECRUITING | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling | Etoposide phosphate is a prodrug that is converted to its active moiety, etoposide, by dephosphorylation | — | targeting, as many cancer cells overexpress folate receptor | checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity |
MoA Biomarker | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | — | — | biomarkers were assessed | biomarkers |
PK/PD Half-life | — | 119 days | — | — | 2 h |
PK/PD Species | Rat | Rabbit | — | Mouse | Mouse |
PK/PD Animal (cat.) | Rat | In vitro | — | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | PK | pharmacokinetic | — | PD | biodistribution |
Toxicology Species | Rat | Rat, Rabbit | — | Mouse, Hamster | Mouse |
Toxicology Animal (cat.) | Rat | Rat | — | Mouse | Mouse, In vitro |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | hepatotoxicity 6 | thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literatur | thrombocytopenia have been reported | hepatotoxicity: knowledge gap identification based on the irAOP concept |
Clinical Primary efficacy | ORR 95.2% | ORR 77.3% | ORR 64% | ORR 95% | ORR 33.3% |
Clinical ORR | 95.2% | 77.3% | 64% | 95.0% | 33.30% |
Clinical PFS | 61.4 | 38 | — | — | — |
Clinical OS | NA | — | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT00732498 | ClinicalTrials.gov NCT01909934 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT01993719 |
Clinical Data Tier / Score | S · 78 | A · 73 | C · 53 | B · 70 | C · 46 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 9일 (5일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교